View Item 

Show simple item record

Safety and efficacy of direct- acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single- center cohort study
dc.contributor.authorBixby, Alexandra L.
dc.contributor.authorShaikh, Suhail A
dc.contributor.authorNaik, Abhijit S.
dc.contributor.authorCotiguala, Laura
dc.contributor.authorMcMurry, Katie
dc.contributor.authorSamaniego‐picota, Milagros D.
dc.contributor.authorMarshall, Vincent D.
dc.contributor.authorPark, Jeong M.
dc.date.accessioned2020-07-02T20:33:35Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-07-02T20:33:35Z
dc.date.issued2020-07
dc.identifier.citationBixby, Alexandra L.; Shaikh, Suhail A; Naik, Abhijit S.; Cotiguala, Laura; McMurry, Katie; Samaniego‐picota, Milagros D. ; Marshall, Vincent D.; Park, Jeong M. (2020). "Safety and efficacy of direct- acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single- center cohort study." Transplant International 33(7): 740-751.
dc.identifier.issn0934-0874
dc.identifier.issn1432-2277
dc.identifier.urihttps://hdl.handle.net/2027.42/155941
dc.publisherBristol- Myers Squibb Company
dc.publisherWiley Periodicals, Inc.
dc.subject.otheranticoagulation
dc.subject.otherkidney transplant
dc.subject.othermajor bleeding
dc.subject.othervitamin K antagonist
dc.subject.otherdirect oral anticoagulant
dc.titleSafety and efficacy of direct- acting oral anticoagulants versus warfarin in kidney transplant recipients: a retrospective single- center cohort study
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155941/1/tri13599.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155941/2/tri13599_am.pdf
dc.identifier.doi10.1111/tri.13599
dc.identifier.sourceTransplant International
dc.identifier.citedreferenceLeon J, Zuber J, Amrouche L, Anglicheau D, Divard G, Legendre C. Novel oral anticoagulants in kidney transplantation: results from a pilote study. Am J Transplant. 2019; 19 ( Suppl. 3 ). https://atcmeetingabstracts.com/abstract/novel-oral-anticoagulants-in-kidney-transplantation-results-from-a-pilote-study/.
dc.identifier.citedreferenceAgnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799.
dc.identifier.citedreferenceConnolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139.
dc.identifier.citedreferenceSchulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342.
dc.identifier.citedreferencePatel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883.
dc.identifier.citedreferenceBauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499.
dc.identifier.citedreferenceVan Der Hulle T, Kooiman J, Den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta- analysis. J Thromb Haemost 2014; 12: 320.
dc.identifier.citedreferenceBruins Slot KMH, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2018; ( 3 ): CD008980.
dc.identifier.citedreferenceAmbrosi P, Kreitmann B, Cohen W, Habib G, Morange P. Anticoagulation with a new oral anticoagulant in heart transplant recipients. Int J Cardiol 2013; 168: 4452.
dc.identifier.citedreferenceBellam N, Kamath M, DePasquale EC, et al. Direct acting oral anticoagulant utilization, safety and efficacy in heart transplant (HT). J Hear Lung Transplant 2018; 37: S112.
dc.identifier.citedreferenceBrown A, Palkimas S, Ally W. Apixaban therapy is safe and effective in most organ transplant populations. Am J Transplant 2019; 19 ( Suppl. 3 ). https://atcmeetingabstracts.com/abstract/apixaban-therapy-is-safe-and-effective-in-most-organ-transplant-populations/.
dc.identifier.citedreferenceDo V, Haakinson D, Belfield K. When to hold: apixaban in renal transplant recipients. Am J Transplant 2019; 19 ( Suppl. 3 ). https://atcmeetingabstracts.com/abstract/when-to-hold-apixaban-in-renal-transplant-recipients/.
dc.identifier.citedreferenceHazelcorn J, Yau R, Sabagha N, Moadda M, Manson M. Risk of major bleeding in solid organ transplant recipients taking calcineurin inhibitors concomitantly with direct oral anticoagulants compared to warfarin. Am J Transplant 2017; 17: 640.
dc.identifier.citedreferenceKim M, Gabardi S, Townsend KR, Page DS, Woodcome EL, Givertz MM. Post transplant thrombosis and atrial arrhythmia may be safely managed by direct oral anticoagulants in cardiac transplant patients. J Hear Lung Transplant 2016; 35: S123.
dc.identifier.citedreferenceLichvar AB, Moore CA, Ensor CR, McDyer JF, Teuteberg JJ, Shullo MA. Evaluation of direct oral anticoagulation therapy in heart and lung transplant recipients. Prog Transplant 2016; 26: 263.
dc.identifier.citedreferenceLoosier T, Guiterrez K, James A, Dodson A. A comparison of the safety and efficacy of apixaban use in renal transplant vs. non- renal transplant recipients. Am J Transplant 2019; 19 ( Suppl. 3 ). https://atcmeetingabstracts.com/abstract/a-comparison-of-the-safety-and-efficacy-of-apixaban-use-in-renal-transplant-vs-non-renal-transplant-recipients/.
dc.identifier.citedreferenceMcMurry K, Shuster J, Bain K, Horwedel T, Hartupee J. Safety and efficacy of anti Xa inhibitors post- transplant with concomitant calcineurin inhibitors. Am J Transplant 2019; 19 ( Suppl. 3 ). https://atcmeetingabstracts.com/abstract/safety-and-efficacy-of-anti-xa-inhibitors-post-transplant-with-concomitant-calcineurin-inhibitors/.
dc.identifier.citedreferencePasley T, Logan A, Brueckner A, Bowman- Anger L, Silverman A, Rumore A. Direct oral anticoagulants: an evaluation of the safety and efficacy in cardiothoracic transplant recipients [abstract]. J Hear Lung Transplant 2019; 38: S304.
dc.identifier.citedreferencePasley T, Logan A, Brueckner A, Bowman L, Silverman A, Rumore A. Direct oral anticoagulants: an evaluation of the safety and efficacy in solid organ transplant recipients. Am J Transplant 2019; 19 ( Suppl. 3 ). https://atcmeetingabstracts.com/abstract/direct-oral-anticoagulants-an-evaluation-of-the-safety-and-ef?cacy-in-solid-organ-transplant-recipients/.
dc.identifier.citedreferenceSanteusansio A, Weinberg A, Schiano T. The comparative safety and efficacy of direct acting oral anticoagulants relative to warfarin following liver transplantation. Am J Transplant 2019; 19 ( Suppl. 3 ). https://atcmeetingabstracts.com/abstract/the-comparative-safety-and-efficacy-of-direct-acting-oral-anticoagulants-relative-to-warfarin-following-liver-transplantation/.
dc.identifier.citedreferenceShaikh S, Samaniego M, Park J. Direct oral anticoagulation use in kidney transplant recipients [abstract]. Am J Transpl 2017; 17 ( Suppl. 3 ): 1.
dc.identifier.citedreferenceShuster JE, LaRue SJ, Vader JM. Dabigatran may have more significant drug interactions with calcineurin inhibitors than oral anti- Xa inhibitors. J Hear Lung Transplant 2016; 35: S417.
dc.identifier.citedreferenceTremblay- Gravel M, Alexander KM, Czobor P, et al. Directly to a DOAC? Safety of alternatives to warfarin for anticoagulation in heart transplantation. J Hear Lung Transplant 2019; 38: S389.
dc.identifier.citedreferenceVanhove T, Spriet I, Annaert P, et al. Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients. Ther Drug Monit 2017; 39: 77.
dc.identifier.citedreferenceWannhoff A, Weiss KH, Schemmer P, Stremmel W, Gotthardt DN. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. Transplantation 2014; 98: 12.
dc.identifier.citedreferenceSahin G, Temiz G, Ozkurt S, et al. Effect of transplant on platelet function markers (P- selectin and platelet aggregation) and adiponectin in renal transplant patients. Exp Clin Transplant 2018; 2: 160.
dc.identifier.citedreferenceSaeed F, Angrawl N, Greenberb E, Holley JL. Lower gastrointestinal bleeding in chronic hemodialysis. Int J Nephrol 2011; 2011: 272535.
dc.identifier.citedreferenceBarnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med 2015; 128: 1300.
dc.identifier.citedreferenceScaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013; 52: 69.
dc.identifier.citedreferenceLenihan CR, Montez- Rath ME, Scandling JD, Turakhia MP, Winkelmayer WC. Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. Am J Transplant 2013; 13: 1566.
dc.identifier.citedreferenceLentine KL, Schnitzler MA, Abbott KC, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 288.
dc.identifier.citedreferenceParajuli S, Lockridge JB, Langewisch ED, Norman DJ, Kujovich JL. Hypercoagulability in kidney transplant recipients. Transplantation 2016; 100: 719.
dc.identifier.citedreferenceAbualhassan N, Aljiffry M, Thalib L, Coussa R, Metrakos P, Hassanain M. Post- transplant venous thromboembolic events and their effect on graft survival. Saudi J Kidney Dis Transpl 2015; 26: 1.
dc.identifier.citedreferenceChrobak K, Debska- Slizien A, Jankowska M, Sledzinski Z, Rutkowski B. The modification of diet in renal disease and chronic kidney disease epidemiology collaboration formulas versus measured or estimated creatinine clearance in kidney transplant recipients. Transplant Proc 2014; 46: 2664.
dc.identifier.citedreferenceSalerno DM, Tsapepas D, Papachristos A, et al. Direct oral anticoagulant considerations in solid organ transplantation: a review. Clin Transplant 2017; 31: e12873.
dc.identifier.citedreferenceSchulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non- surgical patients. J Thromb Haemost 2005; 3: 692.
dc.identifier.citedreferenceKaatz S, Ahmad D, Spyropoulos AC, Schulman S, The Subcommittee on Control of Anticoagulation. Definition of clinically relevant non- major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non- surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13: 2119.
dc.identifier.citedreferenceEliquis ® [package insert]. New York, NY: Bristol- Myers Squibb Company, 2016.
dc.identifier.citedreferenceXarelto ® [package insert ]. Titusville, NJ: Janssen Pharmaceuticals, Inc, 2017.
dc.identifier.citedreferencePradaxa ® [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc, 2017.
dc.identifier.citedreferenceTherneau T. A Package for Survival Analysis in S. version 2.38, 2015. https://CRAN.R-project.org/package=survival.
dc.identifier.citedreferenceTherneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer, 2000. ISBN 0- 387- 98784- 3.
dc.identifier.citedreferenceR Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2019.
dc.identifier.citedreferenceBarnes GD, Lucas E, Alexander G, Goldberger ZD. National trends in ambulatory oral anticoagulation use. Am J Med. 2015; 128: 1300.e2.
dc.identifier.citedreferenceSiontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end- stage kidney disease and atrial fibrillation in the United States. Circulation 2018; 138: 1519.
dc.identifier.citedreferenceGranger CB, Alexander JH, Mcmurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
tri13599.pdf
Size:
370.2KB
Format:
PDF
View/Open
Name:
tri13599_am.pdf
Size:
241.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.